Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-1005 via Prescriptive Infusion Algorithm in Parkinson's Disease
NCT07215403Phase 2Not yet recruiting
- Sponsor
- AskBio
- Start
- Nov 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ametefgene parvec in Parkinson's disease (PD), sponsored by AskBio. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07215403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215403.